Tenapanor's commercial trajectory and CIC label expansion define the thesis; ACCEL Phase 3 readout in H2 2027 is the pivotal test

Bull

A positive readout demonstrating statistically significant improvement in the FDA-defined responder endpoint for CIC — typically ≥1 complete spontaneous bowel movement increase from baseline for ≥9 of 12 weeks — would validate tenapanor's NHE3 mechanism in a broader GI population beyond IBS-C. This would support an sNDA filing and, if approved, meaningfully expand the addressable market for IBSRELA beyond its current IBS-C indication, reinforcing the commercial flywheel already evidenced by the product's 73% revenue growth in 2025.

Bear

The most likely failure mode is missing the primary responder endpoint, which could occur if tenapanor's luminal fluid-secreting mechanism does not produce sufficiently differentiated stool frequency or consistency improvements versus placebo in a CIC population where the mechanism's effect size may be more modest than in IBS-C. A high placebo response rate — a persistent challenge in functional GI trials — or a safety signal around diarrhea-related discontinuations could also undermine the benefit-risk profile and derail the sNDA pathway.